Corrigendum: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.

ARDS COVID - 19 MERS (Middle East respiratory syndrome) SARS SARS - CoV-2 antifibrotics fibrosis

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2020
Historique:
received: 10 09 2020
accepted: 11 09 2020
entrez: 29 3 2021
pubmed: 30 3 2021
medline: 30 3 2021
Statut: epublish

Résumé

[This corrects the article DOI: 10.3389/fmed.2020.00539.].

Identifiants

pubmed: 33777966
doi: 10.3389/fmed.2020.604640
pmc: PMC7992361
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

604640

Commentaires et corrections

Type : ErratumFor

Informations de copyright

Copyright © 2021 Chaudhary, Natt, Bime, Knox and Glassberg.

Auteurs

Sachin Chaudhary (S)

Interstitial Lung Disease Program, University of Arizona Colleges of Medicine, Tucson, AZ, United States.

Bhupinder Natt (B)

Interstitial Lung Disease Program, University of Arizona Colleges of Medicine, Tucson, AZ, United States.

Christian Bime (C)

Interstitial Lung Disease Program, University of Arizona Colleges of Medicine, Tucson, AZ, United States.

Kenneth S Knox (KS)

Banner-University Medicine Division, Phoenix, AZ, United States.

Marilyn K Glassberg (MK)

Banner-University Medicine Division, Phoenix, AZ, United States.

Classifications MeSH